German, Doctors

German Doctors Face €50,000 Annual Loss as Parliament Nears Vote on Health Budget Cuts

Published on 06/29/2026 at 05:53 | Redaktion boerse-global.de

Doctors, municipalities, and pharma warn severe cuts to outpatient care will cause longer waits, fewer appointments, and billions in local costs.

German Health Insurance Savings Law Faces Intense Opposition Ahead of July Vote
German Doctors Face €50,000 Annual Loss as Parliament Nears Vote on Health Budget Cuts Illustration mit AI erstellt übermittelt durch boerse-global.de

Opposition to the planned GKV-Spargesetz (statutory health insurance savings law) is intensifying just weeks before a Bundestag decision scheduled for July 10. Medical associations, municipalities and the pharmaceutical industry are sounding alarms over what they describe as severe cuts to outpatient care.

The Kassenärztliche Vereinigung (KV) Sachsen-Anhalt estimates individual physicians could lose up to €50,000 per year in revenue. The result, the association warns, would be longer waiting times and fewer available appointments for patients.

Andreas Gassen, head of the National Association of Statutory Health Insurance Physicians (KBV), puts the planned savings for 2027 at roughly €2.7 billion. By 2030, the annual figure could reach €5 billion. Items targeted for elimination include appointment incentives, funding for open consultation hours, psychotherapy surcharges and compensation for the electronic patient record (ePA). According to Gassen, approximately 46 million treatment cases could go unpaid or be eliminated entirely in 2027.

Specialists Shift to a Four-Day Week

The Spitzenverband Fachärzte Deutschlands (SpiFa), Germany's umbrella organisation for specialist doctors, is announcing nationwide protests. Starting in 2027, specialist practices plan to open only four days per week across the country, with quarterly closures also in the works. SpiFa chairman Heinrich criticised the law for disproportionately burdening specialists and called for a comprehensive impact assessment.

Structural support is also being hit. KV Berlin will discontinue a subsidy programme for establishing practices in underserved districts from 2027 onward. Previously, grants of up to €70,000 were available there. The association says new KV-affiliated practices are no longer financially viable under the current framework.

Municipalities Warn of Billion-Euro Risks

The German Association of Towns and Municipalities (DStGB) is urging a postponement of the reform. Managing director André Berghegger flags "incalculable risks" for local authorities. A particular flashpoint is the lack of full reimbursement for the health costs of Bürgergeld benefit recipients — these amount to roughly €12 billion per year, with the federal government providing only a flat-rate payment. A planned cap on hospital staffing costs could add around €5 billion to municipal budgets.

Pharma Says Biotech Roadmap in Jeopardy

The association Pharma Deutschland argues that the savings law contradicts the federal government's own declared Biotech Roadmap. Starting in 2027, a dynamic manufacturer discount is scheduled to take effect — initially €1.1 billion, rising to about €5.5 billion by 2030. Additional discounts of 7 percent on vaccines and digital health applications (DiGA) are also planned.

Nursing Insurance: Minister Defends Cuts

Parallel to the GKV reform, Health Minister Warken is defending necessary cutbacks in long-term care insurance, calling the nursing system a "case for rehabilitation." A funding gap of €7.5 billion is expected for 2026.

The reform plans foresee raising the care insurance contribution for childless individuals from 4.2 percent to 4.3 percent. Criteria for care levels (Pflegegrade) would also be tightened. Upgrading to a higher level would only take effect after a six-month waiting period — projected to save €2.6 billion in 2026. Further cuts are planned for subsidies for nursing home residents and pension contributions for family caregivers. Overall, first-year savings are put at €11 billion, rising to more than €20 billion by the end of the decade.

Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.

en | boerse | 69649626 |